zur Navigation zum Inhalt
Onkologie 30. Juni 2011

Novel agents in diffuse large B-cell lymphoma: A short update including ASH 2010

Since the introduction of immunochemotherapy incorporating rituximab and polychemotherapy substantial improvement in the outcome of patients with DLBCL was achieved. Nevertheless, many patients are not cured and prognosis after failure of R-CHOP is scarce. Better understanding of BCR signalling revealed that several new therapeutic targets and new agents such as lenalidomide and bortezomib are now tested in clinical trials as single agent or in combination with established therapies.

Zu diesem Thema wurden noch keine Kommentare abgegeben.

Mehr zum Thema

<< Seite 1 >>

Medizin heute

Aktuelle Printausgaben